CENESTIN Drug Patent Profile

Which patents cover Cenestin, and what generic alternatives are available?

Cenestin is a drug marketed by Aspen and is included in one NDA.

The generic ingredient in CENESTIN is estrogens, conjugated synthetic a. There are three drug master file entries for this compound. Additional details are available on the estrogens, conjugated synthetic a profile page.

Summary for CENESTIN

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for CENESTIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CENESTIN	Tablets	estrogens, conjugated synthetic a	0.3 mg, 0.45 mg and 0.9 mg	020992	1	2009-03-19
CENESTIN	Tablets	estrogens, conjugated synthetic a	0.625 mg	020992	1	2009-03-02
CENESTIN	Tablets	estrogens, conjugated synthetic a	1.25 mg	020992	1	2008-11-03

US Patents and Regulatory Information for CENESTIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aspen	CENESTIN	estrogens, conjugated synthetic a	TABLET;ORAL	020992-001	Jun 21, 2002		DISCN	Yes	No
Aspen	CENESTIN	estrogens, conjugated synthetic a	TABLET;ORAL	020992-003	Mar 24, 1999		DISCN	Yes	No
Aspen	CENESTIN	estrogens, conjugated synthetic a	TABLET;ORAL	020992-005	Feb 5, 2004		DISCN	Yes	No
Aspen	CENESTIN	estrogens, conjugated synthetic a	TABLET;ORAL	020992-002	Mar 24, 1999		DISCN	Yes	No

International Patents for CENESTIN

See the table below for patents covering CENESTIN around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2002504069
Taiwan	457092
China	100421652
World Intellectual Property Organization (WIPO)	9704753

CENESTIN Investment Scenario and Fundamentals Analysis

Last updated: February 3, 2026

Overview

Cenestin is a brand name for a conjugated estrogen therapy primarily used in hormone replacement therapy (HRT) for menopausal women. It is generally marketed as a generic equivalent to Premarin, emphasizing its estrogenic activity derived from conjugated estrogens sourced from pregnant mare's urine. The drug's market relevance is tied to the broader HRT segment, which has faced notable shifts due to regulatory updates and evolving medical guidelines.

Market Landscape

The global hormone replacement therapy (HRT) market was valued at approximately $5.3 billion in 2022, with a compound annual growth rate (CAGR) of around 4% projected through 2030. The growth is driven by aging populations, increasing awareness of menopause management, and the introduction of biosimilars.

Cenestin operates mainly in North America and Europe, where regulatory agencies permit its sale as a generic estrogen therapy. The market is competitive, with key brands including Premarin (ageing patent, off-patent, generic equivalents), Gynodiol, and various biosimilar estrogen products.

Regulatory and Patent Position

Cenestin's formulation is not under patent exclusivity in most jurisdictions. The original conjugated estrogens patent for Premarin expired in the 2000s, which facilitated generic entry. Currently, regulatory approvals are based on bioequivalence studies rather than new clinical trials, which lowers development costs and accelerates market entry.

The US Food and Drug Administration (FDA) approves conjugated estrogens under generic drug applications, provided bioequivalence is demonstrated. The European Medicines Agency (EMA) maintains similar standards. No recent FDA or EMA alerts significantly impact Cenestin's market access.

Financials and Market Penetration

Cenestin's pricing is competitive, with generic estrogen products typically retailing at a 20-30% discount compared to branded Premarin. The profit margins for generics in this segment are narrow, around 10-15%, due to pricing pressures and manufacturing costs.

Market share for Cenestin is estimated at 8-12% within the US generic estrogen segment, with shifts occurring due to clinicians' shifting preferences towards transdermal or bioidentical hormone therapies.

Fundamental Drivers

• Demand Drivers:
  Aging female population (US: 44 million women aged 50-64 in 2022), increasing use of HRT for menopause symptoms, and increased insurance coverage for generic drugs.

• Supply Chain Factors:
  Availability and sourcing of conjugated estrogens (mainly from pregnant mare's urine), manufacturing scale, and regulatory compliance impact supply stability.

• Competitive Dynamics:
  Entry of biosimilar estrogen products and preference for non-oral formulations influence market share.

• Regulatory Risks:
  Regulatory shifts or new safety guidelines, such as those related to estrogens' cardiovascular risks, affect overall product demand.

Investment Risks

• Market Saturation:
  High generic penetration decreases margin potential over time.

• Regulatory Changes:
  Potential bans or restrictions on hormone therapy use could reduce demand.

• Public Perception:
  Negative publicity associated with hormone therapy risks impacts prescribers' and patients' preferences.

Growth Outlook

While the size of Cenestin's addressable market remains steady, its growth depends on the expansion of the older female demographic and broader acceptance of generic hormone therapies. Innovation in delivery methods, such as transdermal patches or gels, provides limited benefits for Cenestin’s existing formulation but could affect overall market dynamics.

Conclusion

Cenestin functions within a mature, highly competitive segment of the pharmaceutical industry. Its investment case hinges on continued demand for hormone replacement therapy, stable regulatory environment, and generic market penetration. Margins are constrained by pricing competition and shifting treatment paradigms.

Key Takeaways

• The global HRT market grows at 4% annually, with generics like Cenestin capturing a significant share.

• Patent expirations and regulatory approvals based on bioequivalence support continued market presence.

• Margin pressures and evolving clinical guidelines present investment risks.

• Market share stability depends on generic pricing strategies and prescriber preferences.

FAQs

1. What differentiates Cenestin from other estrogen therapies?
   It is a generic conjugated estrogen derived from pregnant mare's urine, with similar efficacy to branded alternatives like Premarin.

2. How does regulatory approval affect Cenestin's market access?
   Approval based on bioequivalence accelerates entry, with standard regulatory risks applicable.

3. What are the main drivers of demand for Cenestin?
   Aging female populations, menopause management needs, and insurance coverage for generics.

4. What competition exists for Cenestin?
   Other generic conjugated estrogens, biosimilars, and different hormone therapy formulations like transdermal patches.

5. What risks could impact Cenestin's profitability?
   Regulatory restrictions, declining demand due to safety concerns, and increased competition.

References

[1] MarketsandMarkets, "Hormone Replacement Therapy Market," 2022.
[2] FDA, "Generic Drug Approvals," 2023.
[3] IMS Health, "Global Pharmaceutical Market Data," 2022.
[4] European Medicines Agency, "Hormone Therapies," 2023.